Biospective
Biospective is a preclinical neuroscience contract research organization (CRO) that provides validated rodent models and supporting CRO services (in vivo imaging, electrophysiology, biomarkers, histology, spatial biology) to pharmaceutical, biotech, and academic clients developing CNS therapeutics.
- Company typePrivate
- Founded2007
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
Biospective firmographics
Firmographics- Name
- Biospective
- Legal name
- Biospective Inc.
- Website
- https://biospective.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biospective is a preclinical neuroscience contract research organization (CRO) that provides validated rodent models and supporting CRO services (in vivo imaging, electrophysiology, biomarkers, histology, spatial biology) to pharmaceutical, biotech, and academic clients developing CNS therapeutics.
- Ownership category
- akta.pro rank
Biospective industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Biospective is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Biospective business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Preclinical Contract Research Services: Fee-for-service preclinical CRO contracts providing end-to-end research services from model generation to in-life testing to quantitative tissue and fluid biomarker analysis for pharmaceutical and biotech companies developing CNS therapeutics.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Biospective product offering
Product offeringCore offering
Biospective is a preclinical neuroscience contract research organization (CRO) that sells end-to-end research services for CNS drug development programs. Its core offering combines thoroughly characterized transgenic and inducible rodent models of neurodegenerative diseases (ALS, Alzheimer's, Parkinson's, Tauopathies, Multiple Sclerosis) with in-life CRO services including dosing, stereotaxic surgery, behavioral testing, electrophysiology, in vivo imaging (MRI/PET/CT), histopathology, multiplex immunofluorescence, spatial biology analysis, and fluid and cellular biomarker assays. Services are delivered on a fee-for-service project basis to pharmaceutical, biotechnology, and academic research customers.
Product overview
Biospective is a Preclinical Neuroscience CRO providing end-to-end contract research services from model generation to in-life testing to quantitative tissue & fluid biomarkers. Their offering includes thoroughly characterized and validated rodent models of neurological diseases (ALS, Alzheimer's Disease, Parkinson's Disease, Tauopathies, Multiple Sclerosis) along with comprehensive CRO services including Animal Services (dosing, stereotaxic surgery, tissue collection), Behavioral Testing, Electrophysiology, Fluid & Cell Biomarkers, Histology & IHC/mIF, In Vivo Imaging (MRI, PET, CT), and Spatial Biology. The company also operates a Microglia, Astrocytes, and Neurodegenerative Diseases Initiative for scientific research advancement.
Differentiator
Problem solved
Functional benefit
Brands
- Microglia, Astrocytes, and Neurodegenerative Diseases Initiative: An initiative exploring the complex relationships between neuroinflammation and neurodegeneration, aiming to enhance scientific knowledge and accelerate the development of disease-modifying therapies for ALS, Alzheimer's Disease, Tauopathies, and Parkinson's Disease.
Products and services
- Amyotrophic Lateral Sclerosis (ALS) Rodent Models TDP-43 transgenic rodent models that recapitulate ALS pathology, including the rNLS8 TDP-43ΔNLS model exhibiting cytoplasmic aggregates, motor dysfunction, neurodegeneration, neuroinflammation, and neuromuscular changes. Used by pharmaceutical and biotech sponsors developing ALS therapeutics.
- Alzheimer's Disease Rodent Models Amyloid-β and tau rodent models with progressive pathologic changes in a well-defined spatiotemporal pattern, including the APP/PS1 amyloid-β transgenic mouse model and the Amyloid-Beta & Tau Co-Pathology mouse model. Used by sponsors developing Alzheimer's Disease therapeutics.
- Parkinson's Disease Rodent Models α-Synuclein preformed fibril (PFF) seeding and spreading rodent models and AAV-induced α-synuclein mouse models, including the A53T variant, recapitulating different aspects of Parkinson's Disease pathology. Used by sponsors developing PD therapeutics.
- Tauopathies Rodent Models Tau rodent models with progressive pathologic changes in a well-defined spatiotemporal pattern, including AAV Tau models of PSP & CBD and Tau Preformed Fibril (PFF) Seeding mouse models. Used by sponsors developing therapeutics for tauopathies.
- Multiple Sclerosis (MS) Rodent Models EAE, cuprizone, and other rodent models that recapitulate autoimmune inflammation, demyelination & remyelination, and neurodegeneration aspects of human Multiple Sclerosis. Used by sponsors developing MS therapeutics.
- Animal Services In-life CRO services including dosing via multiple routes of administration, stereotaxic surgical procedures, and fluid & tissue collection, supporting preclinical CNS studies. Delivered to pharmaceutical, biotech, and academic customers.
- Behavioral Testing Specific, validated behavioral tests sensitive to response to therapy in CNS rodent models, covering motor & sensory function and sleep & cognition. Delivered to sponsors evaluating CNS therapeutics.
- Electrophysiology In vivo electrophysiological measures including CMAP & MUNE for motor function and CNAP for sensory function evaluation in CNS rodent models. Delivered to sponsors assessing neuromuscular and sensory endpoints.
- Fluid & Cell Biomarkers Measurement of clinically translational biomarkers including neurofilament light chain (NfL), Aβ40/Aβ42, Total Tau/pTau, cytokines, and chemokines in blood and cerebrospinal fluid, plus cellular immunophenotyping on brain, spinal cord, lymph nodes, and spleen tissues. Delivered to sponsors requiring translational biomarker readouts.
- Histology & IHC/mIF State-of-the-art histopathology facility specializing in tissues from rodent models of neurological diseases, including Immunohistochemistry (IHC) and Multiplex Immunofluorescence (mIF) for analysis of amyloid plaques, microglia, neuromuscular junction, and tau. Delivered to sponsors requiring tissue-based endpoints.
- In Vivo Imaging Preclinical MRI, PET, and CT scanners with advanced image processing and analysis techniques to non-invasively measure changes in brain and muscle structure and function. Delivered to sponsors requiring longitudinal non-invasive imaging endpoints.
- Spatial Biology Analysis of spatial relationships on multiplex immunofluorescence images using sophisticated algorithms, enabling sponsors to extract spatial tissue readouts from mIF data.
Companies that use Biospective
Customer profileSegments2 records
Ideal customer profiles2 records
Biospective technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Biospective partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights5 records
Biospective competitors and assessment
Company assessmentDirect peers
- PsychoGenics: PsychoGenics is a preclinical CRO specializing in CNS/neurological disease models with behavioral phenotyping and electrophysiology, making it the closest direct competitor to Biospective in neurodegenerative preclinical services.
- Inotiv: Inotiv provides preclinical CRO services including rodent models, safety assessment, and research models with a focus on discovery and translational research, directly competing with Biospective in neurodegenerative and CNS preclinical studies.
Broad incumbents
- Charles River Laboratories: Charles River is a global full-service preclinical CRO offering rodent models, safety assessment, and discovery services for CNS programs. It competes with Biospective on neurodegeneration models while serving many other therapeutic areas.
- Labcorp (Covance Early Development): Labcorp's early development/Covance business provides preclinical CRO services including rodent efficacy/safety models relevant to Biospective's CNS offering, with much broader global scale.
- WuXi AppTec: WuXi AppTec operates one of the largest global preclinical CRO networks with rodent model services and in vivo pharmacology capabilities spanning CNS, making it a broad incumbent peer in Biospective's category.
- Crown Bioscience (JSR Life Sciences): Crown Bioscience provides preclinical CRO services including translational oncology and CNS-relevant models with in vivo imaging, positioned as a comparable preclinical CRO with broader therapeutic reach than Biospective.
Emerging players
- MD Biosciences: MD Biosciences is a preclinical CRO offering rodent models and efficacy services in inflammation, neurology, and pain, with overlapping CNS/neurodegenerative capabilities to Biospective but at smaller scale.
- Sylics (an OcellO company): Sylics (part of OcellO) provides preclinical CNS/neuroscience CRO services with automated behavioral phenotyping in rodent models, a niche emerging peer to Biospective's CNS preclinical offering.
- Biocytogen: Biocytogen offers preclinical CRO services with extensive transgenic/knockout rodent model libraries and in vivo pharmacology, including CNS disease models, positioning it as an emerging alternative to specialized neuroscience CROs.
Others
- Clario (formerly Bioclinica/ERT): Clario provides clinical imaging and eCOA/eClinical solutions for CNS clinical trials and runs clinical imaging core labs, paralleling Biospective's clinical Imaging CRO arm rather than its preclinical rodent business.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Biospective social profiles
Digital presenceBiospective financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biospective leadership team
Management profileNumber of profiles
Biospective funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biospective M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biospective
What does Biospective do?
Biospective is a preclinical neuroscience contract research organization (CRO) that sells end-to-end research services for CNS drug development programs. Its core offering combines thoroughly characterized transgenic and inducible rodent models of neurodegenerative diseases (ALS, Alzheimer's, Parkinson's, Tauopathies, Multiple Sclerosis) with in-life CRO services including dosing, stereotaxic surgery, behavioral testing, electrophysiology, in vivo imaging (MRI/PET/CT), histopathology, multiplex immunofluorescence, spatial biology analysis, and fluid and cellular biomarker assays. Services are delivered on a fee-for-service project basis to pharmaceutical, biotechnology, and academic research customers.
Is Biospective a public or private company?
Biospective is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Biospective founded?
Biospective was founded in 2007. It employs 11 to 50 people.
Where is Biospective based?
Biospective is headquartered in Montréal, Canada, in the North America region.
How does Biospective make money?
One revenue line is on record: preclinical Contract Research Services.
Who are Biospective's main competitors?
Direct peers on record are PsychoGenics and Inotiv. Broad incumbents are Charles River Laboratories, Labcorp (Covance Early Development), WuXi AppTec and Crown Bioscience (JSR Life Sciences). Emerging players are MD Biosciences, Sylics (an OcellO company) and Biocytogen. Clario (formerly Bioclinica/ERT) is listed as an others.
Does Biospective have an API?
No public API is recorded for Biospective.
What industry is Biospective in?
Biospective's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8731.